| 000 | 01408 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513050127.0 | ||
| 264 | 0 | _c19950330 | |
| 008 | 199503s 0 0 eng d | ||
| 022 | _a0021-5198 | ||
| 024 | 7 |
_a10.1254/jjp.66.303 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSugiyama, A | |
| 245 | 0 | 0 |
_aUtilization of an isolated, blood-perfused canine papillary muscle preparation as a model to assess efficacy and adversity of class I antiarrhythmic drugs. _h[electronic resource] |
| 260 |
_bJapanese journal of pharmacology _cNov 1994 |
||
| 300 |
_a303-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xpharmacology |
| 650 | 0 | 4 |
_aCoronary Circulation _xdrug effects |
| 650 | 0 | 4 | _aCross Circulation |
| 650 | 0 | 4 | _aDogs |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Conduction System _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardial Contraction _xdrug effects |
| 650 | 0 | 4 |
_aPapillary Muscles _xdrug effects |
| 650 | 0 | 4 |
_aTetrodotoxin _xpharmacology |
| 650 | 0 | 4 |
_aVerapamil _xpharmacology |
| 700 | 1 | _aMotomura, S | |
| 700 | 1 | _aHashimoto, K | |
| 773 | 0 |
_tJapanese journal of pharmacology _gvol. 66 _gno. 3 _gp. 303-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1254/jjp.66.303 _zAvailable from publisher's website |
| 999 |
_c7868953 _d7868953 |
||